The PANACEA Horizon program has delivered one if its key milestones in new probe technology for characterization of advanced pharmaceutical formulations containing Fluorine atoms – check out our recent publication in J Magn Res.
The new capability resulting from this industry-academia collaboration (AZ/Bruker/University of Gothenburg/CNRS Lyon/EPFL Lausanne), has been installed at the Swedish NMR Centre in Gothenburg and is now open for applications for all partners and where AZ has a unique opportunity to collaborate.
The publication exemplifies applications across Discovery-PharmSci-Product Development, demonstrating superior high-sensitive detection of siRNAs, amorphous nanoparticles (AZD2811) as well as surfaces of microcrystalline drug substances.
